The first active compound with large clinical applications in CML was imatinib [26] followed by dasatinib, which binds BCR-ABL1 and other oncogenic kinases, such as SRC family kinases in both configurations of inactive or active kinase state [27]. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.